@article{316c59075a82456fb7d1e605af019373,
title = "Cardiovascular health of patients with cancer and cancer survivors: A roadmap to the next level",
abstract = "Many existing and emerging cancer therapies have a significant effect on the cardiovascular health of patients with cancer and cancer survivors. This paper examines current aspects of interdisciplinary cardio-oncology clinical care delivery and education in the United States and outlines how these data provide a platform for future development of the field. We present the results of the nationwide survey on cardio-oncology services, practices, and opinions, conducted among chiefs of cardiology and program directors, which demonstrate ranges of clinical activities and identify significant interest for increased educational opportunities and expert training of cardiovascular physicians in this field. The survey respondents recognized clinical relevance but emphasized lack of national guidelines, lack of funds, and limited awareness and infrastructure as the main challenges for development and growth of cardio-oncology. We discuss potential solutions to unmet needs through interdisciplinary collaboration and the active roles of professional societies and other stakeholders.",
keywords = "cancer survivorship, cardio-oncology, cardiovascular risk prevention, cardiovascular toxicity",
author = "Ana Barac and Gillian Murtagh and Carver, {Joseph R.} and Chen, {Ming Hui} and Freeman, {Andrew M.} and Joerg Herrmann and Cezar Iliescu and Bonnie Ky and Mayer, {Erica L.} and Okwuosa, {Tochi M.} and Plana, {Juan Carlos} and Ryan, {Thomas D.} and Rzeszut, {Anne K.} and Douglas, {Pamela S.}",
note = "Funding Information: The views expressed in this paper by the American College of Cardiology's Prevention of Cardiovascular Disease Section do not necessarily reflect the views of the Journal or the American College of Cardiology. This work was supported in part by NIH/5KL2TR000102-04 (to Dr. Barac). Dr. Barac has received research support from the National Institutes of Health ; research support and honoraria for lectures from Genentech, Inc. ; and consultancy fees from Cell Therapeutics, Inc. Dr. Murtagh will be an employee of Abbott Diagnostics in July 2015 but was not affiliated with this company at the time this paper was written. Dr. Freeman has served as a consultant to Gilead; and has served as a speaker for Medtronic. Dr. Hermann has served as a consultant to ARIAD Pharmaceuticals and Bristol-Myers Squibb; and as a member of advisory boards for ARIAD Pharmaceuticals and Bristol-Myers Squibb. Dr. Ky has received research support from Pfizer , the National Institutes of Health , and PA Cure Health . Dr. Mayer has received research support from Pfizer , Eisai , and Myriad . Dr. Douglas has received research grants from the National Cancer Institute and the University of South Florida . All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Publisher Copyright: {\textcopyright} 2015 American College of Cardiology Foundation.",
year = "2015",
month = jun,
day = "30",
doi = "10.1016/j.jacc.2015.04.059",
language = "English (US)",
volume = "65",
pages = "2739--2746",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "25",
}